How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comA Phase 2, Open-label, Non-randomized, Single Center Study to Explore Diagnostic Performance of [18F]fluoroestradiol (FES) Positron Emission Tomography/computed Tomography for the Assessment of Axillary Lymph Node Metastasis in Estrogen-positive Breast Cancer
Description:
This study aims to explore the diagnostic performance of [18F]FES PET/CT for the evaluation of axillary lymph node metastasis in patients with ER-positive breast cancer having clinically suspected or confirmed axillary lymph node metastasis.
Sponsor:
Asan Medical Center
Phase:
Phase 2
Contacts:
Sangwon Hanhswon87@amc.seoul.kr
+82-2-3010-0657
Jaeeun Kimkje0216@amc.seoul.kr
+82-2-3010-4572
Government Study Link:
NCT06695039 - Click here to see study onClinicalTrials.gov
[18F]FES
Isotope(s):
FLUORINE-18
Radioisotope: F-18
Theranostic Role: PET Imaging
T1/2 (Half-Life): 1.8 Hours
Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
Energy: Eβ+ 635 keV
Range: N/A
Decay Daughters: O18 (Stable)
Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
Target(s):
- 17β-estradiol
Share your feedback
Help us improve your experience